• CXCR4 Theranostics in Lymphoma: Imaging and Therapy

  2026-08-10

  This 2026 review explains how CXCR4 biology connects lymphoma imaging with targeted and radioligand therapy. Its main contribution is an integrated view of receptor expression, molecular imaging, treatment selection, and translational limitations, including physiological uptake and compensatory CXCR7 signaling.

• Z-VAD-FMK in Ferroptosis Assay Design

  2026-08-09

  Discover how Z-VAD-FMK can function as a mechanistic apoptosis control when studying ferroptosis propagation, caspase activity measurement, and spatial cell-death signaling. This article translates recent membrane-contact findings into practical assay-design decisions without confusing caspase blockade with ferroptosis inhibition.

• Aβ42, ATP, and P2Y2R-Driven Microglial Clearance

  2026-08-08

  Kim et al. identified an ATP/UTP–P2Y2 receptor pathway through which Aβ1–42-treated microglia increase neighboring-cell migration, peptide uptake, and intracellular degradation. The work reframes extracellular nucleotides as active regulators of amyloid clearance and provides a useful experimental framework combining aggregation-state comparisons, enzymatic nucleotide depletion, receptor-null cells, and pathway inhibition.

• Z-VDVAD-FMK: From Caspase Biology to Viral Defense

  2026-08-07

  Z-VDVAD-FMK offers a practical way to interrogate caspase-2-centered apoptosis while exposing the interpretive limits of pharmacological inhibition. This thought-leadership article connects mitochondrial apoptosis assays with emerging host–Senecavirus A biology and outlines a translational validation strategy.

• BI 2536 in Cancer Research: Precision Control and Dual-Metri

  2026-08-07

  Explore how BI 2536, a potent PLK1 inhibitor, advances cancer research by enabling precise control of cell cycle arrest and apoptosis. This article uniquely integrates dual-metric evaluation insights for a deeper understanding of drug responses.

• Ruxolitinib Phosphate (INCB018424): Precision in JAK/STAT Mo

  2026-08-06

  Ruxolitinib phosphate (INCB018424) enables targeted JAK/STAT signaling pathway modulation, empowering researchers to dissect cytokine signaling in models of inflammation and aggressive cancer. This guide provides actionable protocols, troubleshooting tips, and insight into leveraging recent breakthroughs for robust experimental outcomes.

• SCH772984 HCl: Precision ERK1/2 Inhibition for Cancer Models

  2026-08-06

  Explore how SCH772984 HCl, a highly selective ERK1/2 inhibitor, transforms mechanistic cancer and stem cell research. This article offers unique protocol guidance and deep analysis on leveraging ERK pathway modulation for advanced models.

• Atorvastatin (SKU C6405): Reliable Solutions for Cell Assays

  2026-08-05

  This article delivers scientific, scenario-driven guidance on using Atorvastatin (SKU C6405) for cell viability, proliferation, and cytotoxicity assays in biomedical research. By addressing real laboratory challenges—from experimental design to product selection—it equips researchers with evidence-backed recommendations and protocol parameters. APExBIO’s Atorvastatin is highlighted for its reproducibility and suitability across cardiovascular and oncology research workflows.

• Applied Use of α-Linolenic Acid in Lipid Metabolism Research

  2026-08-05

  Harness α-Linolenic Acid (ALA) for precise modulation of lipid metabolism, inflammation, and cardiovascular pathways in both cell-based and in vivo models. This guide details robust workflows, protocol enhancements, and troubleshooting strategies that empower researchers to maximize reproducibility and biological insight using APExBIO’s high-purity ALA.

• Comparative Antibacterial Activity of N-Formimidoyl Thienamy

  2026-08-04

  This study evaluated the antibacterial spectrum and efficacy of N-formimidoyl thienamycin (MK0787) in direct comparison with ampicillin sodium and other advanced β-lactam antibiotics against resistant clinical isolates. The findings provide critical insights for antibiotic resistance research and inform the selection of β-lactam agents for challenging pathogens.

• Indomethacin: Translational Leverage in Adipocyte and Inflam

  2026-08-04

  This thought-leadership article explores indomethacin’s multidimensional utility as a research-grade nonsteroidal anti-inflammatory drug (NSAID), emphasizing its mechanistic intersections with adipocyte biology, inflammation, and membrane signaling. Drawing upon recent findings on SEMA3E-driven beige adipocyte differentiation and β-catenin signaling, we provide actionable guidance for translational researchers and position APExBIO’s indomethacin as an essential reagent for reproducible, cutting-edge studies in lipid metabolism and inflammation.

• Diphenyleneiodonium Chloride: Precision Redox and cAMP Probe

  2026-08-03

  Diphenyleneiodonium chloride (DPI) empowers researchers to dissect redox and cAMP signaling pathways with unparalleled specificity, facilitating advanced oxidative stress and cell signaling studies. This guide delivers actionable protocols, troubleshooting strategies, and practical insights to maximize DPI's translational value in experimental workflows.

• CARM1-Targeted Peptide Therapy Suppresses Breast Cancer Prog

  2026-08-03

  A recent study introduces Pi-CARM1, a selective peptide inhibitor of the arginine methyltransferase CARM1, demonstrating robust suppression of breast cancer growth in cellular and mouse models. The findings highlight the therapeutic promise of targeting CARM1, including potential to overcome resistance to endocrine therapy.

• Chloroquine: Autophagy Disruption, Fungal Mechanisms, and Re

  2026-08-02

  Explore Chloroquine as a multifaceted research tool—examining its autophagy inhibition, unique impact on fungal pathogenesis, and advanced use in oncology, virology, and immunology. This article delivers distinctive mechanistic insights and protocol guidance for in-depth experimental design.

• SGC-CBP30: Precision CREBBP/EP300 Bromodomain Inhibition in

  2026-08-01

  SGC-CBP30 enables highly selective inhibition of CREBBP/EP300 bromodomains, empowering researchers to dissect super-enhancer–driven malignancy in cancer biology and epigenetics. By integrating evidence from lung adenocarcinoma models, this guide details optimized workflows, troubleshooting strategies, and practical protocol enhancements for advanced transcriptional coactivator studies.

544 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page